25d agoThe Motley FoolBULLISH 73General
Why Amylyx Pharmaceuticals Stock Skyrocketed Today
GLP-1 drugs aren't just for weight loss.
Archived explainer. For the current picture see today's AMLX page.
Why Is AMYLYX PHARMACEUTICA (AMLX) Stock Up Today?
By the Top Tier Newswire AI Desk · August 19, 2026 at 12:05 AM ET · reviewed against 38 wire stories
AMYLYX PHARMACEUTICA (AMLX) is up +63.84% in the latest session. Our newswire has captured 38 stories on AMLX across 14 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why AMLX stock is up today
Amylyx Pharmaceuticals stock surged 63.84% to $35.11 on Tuesday, marking its best single-day performance. The move was driven by the release of positive phase 3 trial results for its drug candidate avexitide, a GLP-1 receptor antagonist. The news coincided with a $350 million public stock offering to fund commercialization and R&D efforts.
What Happened
Amylyx announced positive data for avexitide, a drug initially developed for amyotrophic lateral sclerosis but now showing potential in weight management. The trial results triggered a sharp rise in investor sentiment, sending shares to a new 52-week high. The company also announced a $350 million common stock offering, with underwriters granted an option to purchase an additional $52.5 million in shares. Proceeds from the offering will be used to expand manufacturing capacity, fund research and development, and support working capital needs.
Mizuho raised its price target for Amylyx to $42, while Baird increased its target to $52 from $28. HC Wainwright & Co. also raised its price target to $55 and maintained a Buy rating. The stock’s surge was also supported by broader market attention, with multiple analysts and financial outlets highlighting the development.
What The Data Shows
The stock has traded in a 52-week range of $7.63 to $24.60 and has a market capitalization of $2.5 billion. Despite the recent rally, the company remains unprofitable, with a trailing twelve-month revenue decline of 100.3% and an EPS of -1.43. On the 52-week tape, the stock printed 69 fresh 52-week highs and six 52-week lows on August 19. Over the past eight sessions, the stock had moved down 1.0% from $21.85 to $21.63 before today’s dramatic reversal.
What To Watch
Amylyx has no upcoming earnings date, but investors should monitor the breadth of analyst coverage and how the stock performs against its new price targets. The $350 million offering and the drug’s commercialization timeline will also be key factors to track in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AMLX by the numbers
Last: $35.11Session: +63.84%7 sessions: +70.27%Coverage: 38 stories / 14 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $2.5B52w: $7.63 to $24.60
The headlines behind the move
25d agoStocktwits NewsBEARISH 28General
AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering
The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.
25d agoSeeking AlphaBEARISH 28General
Amylyx makes $350M public stock offering in wake of avexitide results
Amylyx launches a $350M stock offering after avexitide phase 3 results sent shares up 64%. Read more here.
25d agoInvesting.com Analyst RatingsBULLISH 63Analyst
Mizuho raises Amylyx stock price target to $42 on trial success
Mizuho raises Amylyx stock price target to $42 on trial success
25d agoBarchartBULLISH 73Product/PR
AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial
Amylyx shares rally on promising avexitide, a GLP-1 receptor antagonist, data. But should you load up on AMLX stock on strength today? Let’s find out!
25d agoThe FlyBEARISH 24General
Amylyx announces $350M common stock offering
25d agoStockTitanBEARISH 24General
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Amylyx intends to grant underwriters a 30-day option for up to $52.5M more shares; proceeds would fund manufacturing capacity, R&D and working capital.
25d agoThe FlyBULLISH 63Analyst
Amylyx price target raised to $52 from $28 at Baird
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AMLX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AMLX move explainers: 2026-08-31 · 2026-08-24 · 2026-08-21 · 2026-08-20 · 2026-08-19 · 2026-08-18